๐๐จ๐ง๐ฌ๐ฎ๐ฆ๐๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฃ๐๐๐ญ๐ฌ ๐๐ฑ๐ฉ๐๐ง๐ฌ๐ ๐๐ง๐ ๐๐ฎ๐ข๐ฌ๐๐ง๐๐ ๐จ๐ ๐๐๐๐ข๐๐๐ฅ ๐๐๐ฏ๐ข๐๐ ๐๐ซ๐๐๐ข๐ฌ๐ข๐จ๐ง ๐ข๐ง ๐ ๐๐ฏ๐จ๐ซ ๐จ๐ ๐ ๐๐๐ฅ๐-๐๐ข๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐๐ฎ๐ซ๐ข๐ฌ๐ญ๐ข๐ ๐๐ก๐๐ง ๐๐๐ฉ๐ข๐ง๐ ๐๐๐ง๐ง๐๐๐ข๐ฌ ๐๐ฑ๐ญ๐ซ๐๐๐ญ๐ฌ (๐๐ข๐ฅ): ๐๐๐๐ฉ ๐จ๐ซ ๐ฌ๐ก๐๐ฅ๐ฅ๐จ๐ฐ ๐ฉ๐ฎ๐๐, ๐ฆ๐จ๐ซ๐ ๐จ๐ซ ๐๐๐ฐ๐๐ซ ๐ฉ๐ฎ๐๐๐ฌ, ๐ฐ๐ก๐๐ญ ๐ ๐ข๐ฏ๐๐ฌ ๐ซ๐๐ฅ๐ข๐๐ ๐ญ๐จ ๐จ๐ง๐ ๐ข๐ง๐๐ข๐ฏ๐ข๐๐ฎ๐๐ฅ ๐ข๐ฌ ๐๐ข๐๐๐๐ซ๐๐ง๐ญ ๐๐จ๐ซ ๐๐ง๐จ๐ญ๐ก๐๐ซ. In many jurisdictions, cannabis has transitioned from an illicit drug to a regulated consumer commodity akin […]
Archive for the ‘Regulatory Medical Writing’ Category
๐๐จ๐ง๐ฌ๐ฎ๐ฆ๐๐ซ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฃ๐๐๐ญ๐ฌ ๐๐ฑ๐ฉ๐๐ง๐ฌ๐ ๐๐ง๐ ๐๐ฎ๐ข๐ฌ๐๐ง๐๐ ๐จ๐ ๐๐๐๐ข๐๐๐ฅ ๐๐๐ฏ๐ข๐๐ ๐๐ซ๐๐๐ข๐ฌ๐ข๐จ๐ง ๐ข๐ง ๐ ๐๐ฏ๐จ๐ซ ๐จ๐ ๐ ๐๐๐ฅ๐-๐๐ข๐ญ๐ซ๐๐ญ๐ข๐จ๐ง ๐๐๐ฎ๐ซ๐ข๐ฌ๐ญ๐ข๐
๐๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐๐๐-๐๐ ๐ข๐ง ๐๐๐: ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐๐ฌ, ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ฌ๐ข๐ ๐ง ๐๐๐๐ข๐๐ข๐๐ง๐๐ข๐๐ฌ, ๐๐ง๐ ๐ญ๐ก๐ ๐๐๐ฎ๐ฌ๐๐ฅ ๐๐ฏ๐ข๐๐๐ง๐๐ ๐ ๐๐ฉ ๐๐จ๐ซ ๐๐๐ฑ๐๐๐๐.
๐๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐๐๐-๐๐ ๐ข๐ง ๐๐๐: ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐๐ฌ, ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ฌ๐ข๐ ๐ง ๐๐๐๐ข๐๐ข๐๐ง๐๐ข๐๐ฌ, ๐๐ง๐ ๐ญ๐ก๐ ๐๐๐ฎ๐ฌ๐๐ฅ ๐๐ฏ๐ข๐๐๐ง๐๐ ๐ ๐๐ฉ ๐๐จ๐ซ ๐๐๐ฑ๐๐๐๐. Requires a subscription but free download available through Sept. 24 with this link https://authors.elsevier.com/a/1nYxN4r9Rkz1wZ Conclusion: Rigor without cynicism CTx1000 is not another generic antioxidant or anti-inflammatory shot in the dark. The 14-3-3ฮธ/degron mechanism is biologically sophisticated, mechanistically distinct from […]
๐๐ก๐ ๐ก๐ข๐ ๐ก๐๐ฌ๐ญ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ข๐ฅ๐ฎ๐ซ๐ ๐ซ๐๐ญ๐ ๐๐จ๐ซ ๐๐ง๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐ข๐ง ๐ฆ๐จ๐๐๐ซ๐ง ๐ฆ๐๐๐ข๐๐ข๐ง๐: ๐๐จ๐ฐ ๐๐จ๐ญ๐ก ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐- ๐๐ง๐ ๐ง๐จ๐ง-๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐-๐ญ๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ข๐๐ฌ ๐๐๐ข๐ฅ๐๐ ๐ญ๐จ ๐๐ฅ๐ญ๐๐ซ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐จ๐ฎ๐ซ๐ฌ๐ ๐ข๐ง ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐
The post-2022 period revealed that genuinely novel non-amyloid mechanismsโTREM2 agonism, GLP-1 receptor stimulation, filamin A modulation, and progranulin/sortilin restorationโalso failed to produce clinical benefit at scale despite confirmed target engagement.
Posted in Aging Adults, Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing 
Comments Off on ๐๐ก๐ ๐ก๐ข๐ ๐ก๐๐ฌ๐ญ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ข๐ฅ๐ฎ๐ซ๐ ๐ซ๐๐ญ๐ ๐๐จ๐ซ ๐๐ง๐ฒ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐ข๐ง ๐ฆ๐จ๐๐๐ซ๐ง ๐ฆ๐๐๐ข๐๐ข๐ง๐: ๐๐จ๐ฐ ๐๐จ๐ญ๐ก ๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐- ๐๐ง๐ ๐ง๐จ๐ง-๐๐ฆ๐ฒ๐ฅ๐จ๐ข๐-๐ญ๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐ญ๐ก๐๐ซ๐๐ฉ๐ข๐๐ฌ ๐๐๐ข๐ฅ๐๐ ๐ญ๐จ ๐๐ฅ๐ญ๐๐ซ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐จ๐ฎ๐ซ๐ฌ๐ ๐ข๐ง ๐๐ฅ๐ณ๐ก๐๐ข๐ฆ๐๐ซ’๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐A new oral pill drug for pancreatic cancer extends life on average 13.2 months compared to 6.7 months for harsh chemotherapy.
A new oral pill drug approved by the FDA for treatment of pancreatic cancer extends life on average 13.2 months compared to 6.7 months for harsh chemotherapy.ย The drug operates through a first-in-class “molecular glue” tricomplex mechanism that targets the active, GTP-bound “ON” state of both mutant and wild-type RAS proteins. [1, 2, 3] The FDA […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A new oral pill drug for pancreatic cancer extends life on average 13.2 months compared to 6.7 months for harsh chemotherapy.The Goal of Achieving Medicare-for-All
BRIAHNA JOY GRAY: Let’s talk about something like Medicare for All, which Bernie has already done the work of making popular. It went from a 37% approval prior to 2016 to enjoying 90% approval among Democrats, high 60s% approval among independents, and 49% approval among Republicans even. If you have a so-called socialist, a DSA […]
AAV9 immunogenicity as a scalability trap. PROJECT OPTIMUS to boot.
AAV9 immunogenicity as a scalability trap. PROJECT OPTIMUS to boot. The anti-AAV9 titer cutoff of โค1:50 reflects a real immunological constraint: patients with prior AAV9 exposure mount a neutralizing immune response that reduces transduction efficiency and risks severe inflammation. https://www.sciencedirect.com/science/article/pii/S1359644626001571?dgcid=authorhttps://lnkd.in/g2YVjCDb Pre-existing anti-AAV9 antibodies are present in roughly 30โ50% of the general population, with the exact […]
Posted in Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing Comments Off on AAV9 immunogenicity as a scalability trap. PROJECT OPTIMUS to boot.A methodological audit: Where the glasses may be rose-colored
A methodological audit: Where the glasses may be rose-coloredย https://authors.elsevier.com/a/1nYxN4r9Rkz1wZ The open-label problem KOANEWA is a Phase Ib, open-label, non-randomized, single-dose study (ClinicalTrials.govย identifier: NCT07401121). The CENTAUR trial was open-label in its earliest iterations, and its 25% ALSFRS-R signal dissolved entirely under the blinded conditions of the PHOENIX Phase III trial (https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-topline-results-from-global-phase-3-phoenix-trial-of-amx0035-in-als).(p2),(p3)ย Because the subjective ALSFRS-R is […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on A methodological audit: Where the glasses may be rose-coloredTarget-Specific Organs at Risk and Mitigation Strategies for 212Pb-TAT and FAP-Targeted Analogs
Guth MAS. Implementing 212 Pb-Targeted Alpha Therapy: A Safety-First Theranostic Framework for Clinical Practice. Clin Nucl Med Open. 2026;3(3):DOI: 10.1097/nm9.0000000000000092. Table 1. Target-Specific Organs at Risk and Mitigation Strategies for Pb-212-TAT and FAP-Targeted Analogs Organ/Tissue SSTR2/FAP Expression Primary Radiation Risk Proactive Mitigation and Monitoring Strategy Pituitary Gland High (SUVmax โ 15โ25) Hypopituitarism (central hypothyroidism, hypogonadism, […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on Target-Specific Organs at Risk and Mitigation Strategies for 212Pb-TAT and FAP-Targeted AnalogsTargeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000
For the next two weeks or so, my article “Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000″ is available for reading and downloading for free at this link:ย https://www.sciencedirect.com/science/article/pii/S1359644626001571?dgcid=author After that, the article will go behind a journal paywall for a year or more. The therapeutic landscape […]
Posted in Pharma and Medical Device, Regulatory Medical Writing Comments Off on Targeting TDP-43 in ALS: Regulatory hurdles, trial design deficiencies, and the causal evidence gap for CTx1000๐๐ฌ ๐๐๐-๐๐ ๐ญ๐ก๐ ๐ฅ๐ฒ๐ง๐๐ก๐ฉ๐ข๐ง ๐๐จ๐ซ ๐๐ข๐ง๐๐ข๐ง๐ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐จ๐ซ ๐๐๐?
๐๐ฌ ๐๐๐-๐๐ ๐ญ๐ก๐ ๐ฅ๐ฒ๐ง๐๐ก๐ฉ๐ข๐ง ๐๐จ๐ซ ๐๐ข๐ง๐๐ข๐ง๐ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐จ๐ซ ๐๐๐? Two pathologies, one protein The field has increasingly recognized that TDP-43 dysfunction operates through two parallel mechanisms. The cytoplasmic gain-of-function toxicity that CTx1000 directly targets is only half the story. Equally consequential is the loss of normal nuclear TDP-43 function, particularly its role in RNA splicing […]
Posted in Aging Adults, Pharma and Medical Device, Regulatory Medical Writing Comments Off on ๐๐ฌ ๐๐๐-๐๐ ๐ญ๐ก๐ ๐ฅ๐ฒ๐ง๐๐ก๐ฉ๐ข๐ง ๐๐จ๐ซ ๐๐ข๐ง๐๐ข๐ง๐ ๐ญ๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐จ๐ซ ๐๐๐?